Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns.
about
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsPhenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation
P2860
Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Patient-derived acute myeloid ...... nase phosphorylation patterns.
@en
type
label
Patient-derived acute myeloid ...... nase phosphorylation patterns.
@en
prefLabel
Patient-derived acute myeloid ...... nase phosphorylation patterns.
@en
P2093
P2860
P356
P1476
Patient-derived acute myeloid ...... inase phosphorylation patterns
@en
P2093
Jason R Manro
Keith Shults
Leanne Flye
Lisa Green
Michael Lahn
Thomas Daly
P2860
P356
10.2147/CMAR.S5611
P407
P577
2009-05-15T00:00:00Z